Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. EMEA Innovative Medicine /
    2. European Commission Approves SYLVANT® (siltuximab) as MCD Treatment

    European Commission Approves SYLVANT® (siltuximab) as MCD Treatment

    European Commission Approves SYLVANT® (siltuximab) as a Treatment for Patients with Multicentric Castleman’s Disease (MCD)